<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606097</url>
  </required_header>
  <id_info>
    <org_study_id>17298</org_study_id>
    <nct_id>NCT02606097</nct_id>
  </id_info>
  <brief_title>Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation</brief_title>
  <official_title>A Phase 2 Study of Regorafenib in Metastatic Gastrointestinal Stromal Tumours With C-KIT exon17 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to examine whether regorafenib treatment can help people
      with gastrointestinal stromal tumours (GIST) and have gene mutation on c-kit exon 17. The
      safety of regorafenib treatment is also examined.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall clinical benefit rate</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>complete response (CR), partial response (PR), and stable disease (SD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>till study end, estimated 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>till study end, estimated 3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>Incidence of AEs will be shown and severity will be graded using NCI-CTCAE version 4.0</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical hematology laboratory result by hemoglobin (Hb)</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: g/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical hematology laboratory result by hematocrit (Hct)</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: %)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical hematology laboratory result by platelet count</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: 10^9/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical hematology laboratory result by red blood cell (RBC) count</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: 10^9/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical hematology laboratory result by white blood cell (WBC) count</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: 10^9/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical hematology laboratory result by WBC differential</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: %)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by potassium level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by calcium level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by glucose level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by lactate dehydrogenase (LDH) level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: U/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by blood urea nitrogen (BUN) level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by creatinine level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mg/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by total and direct bilirubin levels</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mg/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by albumin levels</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: g/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by alanine aminotransferase(ALT) levels</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: U/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by aspartate aminotransferase (AST) levels</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: U/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by alkaline phosphatase (ALP) level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: U/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by thyroid-stimulating hormone (TSH) level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mIU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by T3 level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mIU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical biochemistry laboratory result by T4 level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mIU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical urinalysis result by WBC count</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: 10^9/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical urinalysis result by RBC count</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: 10^9/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical urinalysis result by pH level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical urinalysis result by protein level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical urinalysis result by glucose level</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical coagulation results by prothrombin time (PT)</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: sec)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical coagulation results by activated partial thromboplastin time (APTT)</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: sec)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in clinical coagulation results by international normalized ratio (INR)</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in vital signs by respiratory rate</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: times/min)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in vital signs by pulse rate</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: times/min)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in vital signs by systolic blood pressure</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mmHg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in vital signs by diastolic blood pressure</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: mmHg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in vital signs by body temperature</measure>
    <time_frame>till 2 weeks after last dose</time_frame>
    <description>(unit: degree celsius)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Gastrointestinal Stromal Tumour (GIST)</condition>
  <arm_group>
    <arm_group_label>regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>regorafenib 160 mg daily, 3 weeks on/1 week off</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regorafenib</intervention_name>
    <arm_group_label>regorafenib</arm_group_label>
    <other_name>stivarga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        An eligible subject must fulfill all of the following inclusion criteria:

          -  Signed informed consent (IC) obtained before any study specific procedure. Patients
             must be able to understand and willing to sign the written IC.

          -  Pathologically confirmed gastrointestinal stromal tumours.

          -  All patients had received imatinib or sunitinib.

          -  Pathological confirmed c-kit exon 17 mutation.

          -  At least one measurable lesion in a non-irradiated area or allowed to be tracked
             whether there are circumstances recurrence by computed tomography (CT) or magnetic
             resonance imaging (MRI).

          -  Aged &gt; 20 years old.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Life expectancy greater than 12 weeks.

          -  Adequate bone marrow function: 1) Absolutely neutrophil count &gt;= 1.5 x10^9/L or white
             blood cell count (WBC) &gt;= 4x10^9/L; 2) Hemoglobin &gt;= 9 g/dL; 3) Platelet count &gt;=
             100x10^9/L.

          -  Adequate liver function: 1) Total bilirubin &lt;= 1.5x the upper limit of normal (ULN);
             2) Alanine Aminotransferase (ALT) &amp; Aspartate Aminotransferase (AST) &lt;= 2.5x ULN if
             without liver metastasis or &lt;= 5x ULN if with hepatic metastasis; 3) Alkaline
             phosphatase &lt;= 2.5x ULN if without liver metastasis or &lt;= 5x ULN if with hepatic
             metastasis or bone metastasis; 4) Bilirubin &lt; 2x ULN.

          -  Adequate renal function: creatinine &lt;1.5x ULN.

          -  Patients must be accessible for treatment and follow-up in the participating centers.

        Exclusion Criteria:

        Subject will not meet any of the following exclusion criteria:

          -  Major surgery within four weeks prior to entering the study.

          -  Patients with central nervous system (CNS) metastasis, including clinical suspicion.

          -  Patients who are under active or uncontrolled infections.

          -  Patients who with unstable angina (angina symptoms at rest, new-onset angina (begun
             within the last 3 months) or myocardial infarction history 6 months before entry.

          -  Cardiac arrhythmia requiring anti-arrhythmic therapy (beta blockers or digoxin are
             permitted).

          -  Congestive heart failure New York Heart Association (NYHA) class 2.

          -  Uncontrolled hypertension (systolic blood pressure [BP] &gt; 150 mmHg or diastolic
             pressure &gt; 90 mmHg despite optimal medical management.

          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
             within 6 months before the start of study medication.

          -  Patients who are pregnant or with breast feeding.

          -  Other concomitant or previously malignancy within 5 years except for in situ cervix
             cancer or squamous cell carcinoma of the skin treated by surgery only.

          -  Mental status is not fit for clinical trial.

          -  Cannot take study medication orally.

          -  Fertile men and women unless using a reliable and appropriate contraceptive method.

          -  Patients with evidence or history of any bleeding diathesis, irrespective of severity.

          -  Any hemorrhage or bleeding event &gt;= Common Terminology Criteria for Adverse Events
             (CTCAE) Grade 3 within 4 weeks prior to the start of study medication.

          -  Non-healing wound, ulcer, or bone fracture.

          -  Renal failure requiring hemo-or peritoneal dialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun-Nan Yeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor and Chief, Department of Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chun-Nan Yeh, MD</last_name>
    <phone>886-3-3281200</phone>
    <phone_ext>3219</phone_ext>
    <email>yehchunnan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Nan Yeh, MD</last_name>
      <phone>886-3-3281200</phone>
      <phone_ext>3219</phone_ext>
      <email>yehchunnan@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Yeh Chun-Nan</investigator_full_name>
    <investigator_title>Professor and Chief, Department of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

